Drug Profile
DS 2330
Alternative Names: DS 2330a; DS-2330bLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Inc
- Class Hyperphosphataemia therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperphosphataemia
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for phase-I development in Hyperphosphataemia(Combination therapy) in USA (PO, Powder)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Hyperphosphataemia(Combination therapy) in USA (PO, Tablet)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Hyperphosphataemia(Monotherapy) in USA (PO, Powder)